Stocks360

Acerus Pharmaceuticals Corporation (ASP.TO)

Stock analysis · TSX · Healthcare · Drug Manufacturers - Specialty & Generic

Share: Facebook X WhatsApp SMS

Get deeper signals and personalized alerts

Free account signup in under 60 seconds

Create free account → I already have an account
Market Cap
N/A
PE (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
Beta
1.03
Day Range
N/A
52-wk Range
N/A
Avg Volume
N/A
Volume
N/A

Acerus Pharmaceuticals Corporation (ASP.TO) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent
May 10, 2019
EPS $-4.00 vs est. $-2.00
Missed by $2.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Acerus Pharmaceuticals Corporation

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical firm dedicated to the development, production, marketing, and distribution of medications for men's and women's health. Its marketed products include Natesto, a nasal gel used for testosterone replacement therapy in adult males diagnosed with hypogonadism, and Noctiva, a vasopressin analog indicated for the treatment of nocturia stemming from nocturnal polyuria in adults who awaken at least two times per night to void. The company is also developing a pipeline of products such as Lidbree, a short-acting lidocaine formulation delivered into the vaginal mucosal tissue using a proprietary device; Stendra, a PDE5 inhibitor for treating erectile dysfunction; Tefina, a clinical-stage therapy for female sexual dysfunction; and various Noctiva combination products, which are in pre-clinical development stages for conditions including benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. Furthermore, Acerus utilizes the TriVair technology platform for pulmonary and nasal dosing. Distribution of its products occurs via its salesforce in the United States and Canada, and through a network of intern…

Peers

Recent News

  • No recent news available.

Related

Browse more tickers: sitemap